Cytokines as a precipitant of depressive illness: Animal and human studies

被引:159
作者
Anisman, H [1 ]
Merali, Z
Poulter, MO
Hayley, S
机构
[1] Carleton Univ, Inst Neurosci, Ottawa, ON K1S 5B6, Canada
[2] Univ Ottawa, Royal Ottawa Hosp, Mental Hlth Res Inst, Ottawa, ON, Canada
关键词
cytokines; cortisol; corticotropin releasing hormone; depression; dopamine; hypothalamic-pituitary-adrenal axis; interleukin; norepinephrine; serotonin;
D O I
10.2174/1381612053381701
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytokines whose primary function is that of acting as signaling molecules of the immune system, have been implicated in the provocation or exacerbation of mood disorders such as depression. This position has been supported by several lines of evidence; (1) proinflarnmatory cytokines (interleukin-1beta, interleukin-6, tumor necrosis factor-alpha) and bacterial endotoxins elicit sickness behaviors (e.g., fatigue, soporific effects) and symptoms of anxiety/depression that may be attenuated by chronic antidepressant treatment. Interleukin-2 (IL-2) induces less profound sickness, but elicits anhedonia, a key symptom of depression; (2) neuroendocrine and central neurotransmitter changes, reminiscent of those implicated in depression, may be elicited by some of these cytokines, and these effects are exacerbated by stressors; (3) severe depressive illness is accompanied by elevations of cytokine production or levels, although these effects are not necessarily attenuated with antidepressant medication; and (4) immunotherapy, using IL-2 or IFN-alpha, promote depressive symptoms that are attenuated by antidepressant treatment. It is proposed that chronic cytokine elevations engender neuroendocrine and brain neurotransmitter changes that are interpreted by the brain as being stressors, and contribute to the development of depression. Further, the effects of the cytokine treatments may act synergistically with stressors, and cytokines may provoke a sensitization effect so that the effects of later stressor experiences are exacerbated.
引用
收藏
页码:963 / 972
页数:10
相关论文
共 117 条
[21]   Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy [J].
Capuron, L ;
Raison, CL ;
Musselman, DL ;
Lawson, DH ;
Nemeroff, CB ;
Miller, AH .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (07) :1342-1345
[22]   Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy [J].
Capuron, L ;
Ravaud, A ;
Neveu, PJ ;
Miller, AH ;
Maes, M ;
Dantzer, R .
MOLECULAR PSYCHIATRY, 2002, 7 (05) :468-473
[23]   Neurobehavioral effects of interferon-α in cancer patients:: Phenomenology and paroxetine responsiveness of symptom dimensions [J].
Capuron, L ;
Gumnick, JF ;
Musselman, DL ;
Lawson, DH ;
Reemsnyder, A ;
Nemeroff, CB ;
Miller, AH .
NEUROPSYCHOPHARMACOLOGY, 2002, 26 (05) :643-652
[24]   Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy [J].
Capuron, L ;
Ravaud, A ;
Gualde, N ;
Bosmans, E ;
Dantzer, R ;
Maes, M ;
Neveu, PJ .
PSYCHONEUROENDOCRINOLOGY, 2001, 26 (08) :797-808
[25]   Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state [J].
Capuron, L ;
Ravaud, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (17) :1370-1370
[26]  
CAPURON L, 2000, AM J PSYCHIAT, V26, P1342
[27]   NEUROPSYCHOLOGICAL AND NEUROPHYSIOLOGICAL ASSESSMENT OF THE CENTRAL EFFECTS OF INTERLEUKIN-2 ADMINISTRATION [J].
CARACENI, A ;
MARTINI, C ;
BELLI, F ;
MASCHERONI, L ;
RIVOLTINI, L ;
ARIENTI, F ;
CASCINELLI, N .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (09) :1266-1269
[28]   IMMUNITY AND DEPRESSION - INSOMNIA, RETARDATION, AND REDUCTION OF NATURAL-KILLER-CELL ACTIVITY [J].
COVER, H ;
IRWIN, M .
JOURNAL OF BEHAVIORAL MEDICINE, 1994, 17 (02) :217-223
[29]  
Dantzer R, 2001, ANN NY ACAD SCI, V933, P222
[30]   The non-steroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysaccharide-induced alterations to reward behavior and corticosterone release [J].
De La Garza, R ;
Fabrizio, KR ;
Radoi, GE ;
Vlad, T ;
Asnis, GM .
BEHAVIOURAL BRAIN RESEARCH, 2004, 149 (01) :77-85